Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | IGLV6-57 | P01721 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30762907 | 0.88 | CA9 (0.58) | ALDH1A1HPGDKDM4EGAAGLA | |
| SCHEMBL20839393 | 0.88 | CA9 (0.58) | ALDH1A1HPGDKDM4EGAAGLA | |
| SCHEMBL20839422 | 0.85 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4EGAAGLA | |
| SCHEMBL30762895 | 0.85 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4EGAAGLA | |
| SCHEMBL28444475 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4EGAAGLA | |
| SCHEMBL20839059 | 0.81 | ALDH1A1 (0.77) | ALDH1A1HPGDKDM4EKMT2AUSP2 | |
| SCHEMBL30228298 | 0.81 | ALDH1A1 (0.77) | ALDH1A1HPGDKDM4EKMT2AUSP2 | |
| SCHEMBL20839056 | 0.81 | ALDH1A1 (0.77) | ALDH1A1HPGDKDM4EKMT2AUSP2 | |
| SCHEMBL30231772 | 0.81 | ALDH1A1 (0.74) | ALDH1A1HPGDKDM4EGAAKMT2A | |
| SCHEMBL30231784 | 0.80 | KDM4E (0.67) | ALDH1A1HPGDKDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, UQCRC2, UQCRC1 | ALDH1A1 1261/4885HPGD 947/4885KDM4E 2362/4885 |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, UQCRC2, UQCRC1 | ALDH1A1 1261/4885HPGD 947/4885KDM4E 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.